Publications — Radcliffe Department of Medicine

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Hepatocyte mARC1 promotes fatty liver disease

Lewis LC. et al, (2023), JHEP Reports, 5

MLX plays a key role in lipid and glucose metabolism in humans: evidence from in vitro and in vivo studies

NAGARAJAN S. et al, (2023), Metabolism: clinical and experimental

Nutritional regulation of hepatic de novo lipogenesis in humans.

Cross E. et al, (2023), Curr Opin Clin Nutr Metab Care, 26, 65 - 71

11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial.

Othonos N. et al, (2023), Nat Commun, 14

An optimised protocol for the investigation of insulin signalling in a human cell culture model of adipogenesis.

Gamwell JM. et al, (2023), Adipocyte

Detection and alterations of acetylcarnitine (AC) in human liver by 1 H MRS at 3T after supplementation with l-carnitine.

Savic D. et al, (2022), Magn Reson Med

Determining the temporal, dose, and composition effects of nutritional substrates in an in vitro model of intrahepatocellular triglyceride accumulation.

Nagarajan SR. et al, (2022), Physiol Rep, 10

The PNPLA3 I148M variant increases intrahepatic lipolysis and beta oxidation and decreases de novo lipogenesis and hepatic mitochondrial function in vivo in humans

Luukkonen PK. et al, (2022), DIABETOLOGIA, 65, S76 - S76

Intrahepatic triglyceride content: influence of metabolic and genetics drivers.

Dearlove DJ. and Hodson L., (2022), Curr Opin Clin Nutr Metab Care, 25, 241 - 247

The PNPLA3 I148M variant increases intrahepatic lipolysis and beta oxidation and decreases de novo lipogenesis and hepatic mitochondrial function in humans

Luukkonen P. et al, (2022), JOURNAL OF HEPATOLOGY, 77, S690 - S691

Acute intermittent hypoxia drives hepatic de novo lipogenesis in humans and rodents.

Hazlehurst JM. et al, (2022), Metabol Open, 14

The effects of endogenously- and exogenously-induced hyperketonemia on exercise performance and adaptation.

Dearlove DJ. et al, (2022), Physiol Rep, 10

Obesity due to Steroid Receptor Coactivator-1 deficiency is associated with endocrine and metabolic abnormalities.

Cacciottolo TM. et al, (2022), J Clin Endocrinol Metab

Water-Only Look-Locker Inversion recovery (WOLLI) T1 mapping

Garrison LD. et al, (2022)

Soat2 ties cholesterol metabolism to β-oxidation and glucose tolerance in male mice.

Pramfalk C. et al, (2022), J Intern Med

Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis.

Green CJ. et al, (2022), Eur J Endocrinol

Dysregulation of hepatic metabolism with obesity: factors influencing glucose and lipid metabolism

Nagarajan SR. et al, (2021), Proceedings of the Nutrition Society, 1 - 23

Bariatric surgery restores dysregulated hepatic lipid metabolism and promotes regression across the spectrum of NAFLD

Dempster N. et al, (2021), OBESITY SURGERY, 31, S16 - S16

Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease.

Luukkonen PK. et al, (2021), J Hepatol

Overfeeding Saturated Fat Increases LDL (Low-Density Lipoprotein) Aggregation Susceptibility While Overfeeding Unsaturated Fat Decreases Proteoglycan-Binding of Lipoproteins.

Ruuth M. et al, (2021), Arterioscler Thromb Vasc Biol

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?